Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea

Salam, I. M. A.; Katelaris, Peter; Farthing, M. J. G.; Leigh-Smith, Simon

doi:10.1016/s0140-6736(94)90350-6

Cited by 124 publications

(46 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fluoroquinolones are effective in both the treatment, even in a single dose (23), and the prophylaxis of traveler's diarrhea (2,23,30,31). They are also the agents of choice in the management of invasive salmonellosis in AIDS patients.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activities of New Fluoroquinolones against Campylobacter jejuni and Campylobacter coli Isolates Obtained from Humans in 1980 to 1982 and 1997 to 2001

Krausse

Ullmann

2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The antibacterial activities of three newly developed fluoroquinolones (gatifloxacin, levofloxacin, and moxifloxacin) against a total of 307 gastrointestinal human isolates of Campylobacter jejuni and Campylobacter coli collected during 1980 to 1982 and 1997 to 2001 were examined and compared to those of ciprofloxacin and the unrelated antibacterial agents, clarithromycin, erythromycin, and tetracycline by using the agar plate dilution method. All of the fluoroquinolones exhibited a good activity against Campylobacter, and some of them were more active than ciprofloxacin, the macrolides, and tetracycline. Among the fluoroquinolones, gatifloxacin and moxifloxacin showed the highest anticampylobacter activity, with MICs at which 50% of the isolates tested are inhibited (MIC 50 s) and MIC 90 s of 0.125 and 4 g/ml, respectively; the MIC 50 for both levofloxacin and ciprofloxacin was 0.25, and the MIC 90 s were 16 and 32 g/ml, respectively. About 30% of the strains were found to be resistant to at least one fluoroquinolone. Resistance to gatifloxacin occurred in 9.8% of the isolates tested, and resistance to the other fluoroquinolones occurred in 19.9 to 27.4% of the isolates tested; the frequency of cross-resistance was 35.7 to 100%. An increase in fluoroquinolone resistance from 0% in 1980 to 1982 to 11.8 to 29% in 1997 and 1998, 8.2 to 31.8% in 1999 and 2000, and 12.1 to 30.3% in 2001 was found. A total of 61.4 to 73.2% of the C. jenuni strains resistant to erythromycin, clarithromycin, and/or tetracycline were susceptible to fluoroquinolones; gatifloxacin showed the highest percentage of inhibition. These results show that the newer fluoroquinolones with their potent activity could be used to treat infections with C. jejuni and C. coli. However, when these drugs are used, one must consider the increase in resistance and the high cross-resistance to these antimicrobial agents.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vitro Activities of New Fluoroquinolones against Campylobacter jejuni and Campylobacter coli Isolates Obtained from Humans in 1980 to 1982 and 1997 to 2001

Krausse

Ullmann

2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Salam ve ark. [8] son 24 saatte turist diyaresi başlayan 83 hastaya tek doz 500 mg ciprofloxacin ve placebo vermiştir; 24 saat sonunda forme gaitası olan hasta oranı tedavi grubunda %64, plasebo grubunda ise %11, 48. saatte %82 vv %42, 72. saatte ise %93 ve %79 olarak saptanmıştır. Yine Salam ve ark.…”

Section: Metodolojiunclassified

Current Clinical Management Suggestions: Emergency Department Management of a Patient with Acute Diarrhea

Eken

2011

Tr J Emerg Med

View full text Add to dashboard Cite

“…39 40 Similar efficacy has also been shown with single dose regimens. 41 Recently, there has been renewed interest in a non-absorbed locally active antibiotic, rifaximin, for the treatment of traveller's diarrhoea. This drug has been shown to be as effective as ciprofloxacin but with the potential advantage of only minimal systemic absorption.…”

Section: Acute Watery Diarrhoeamentioning

confidence: 99%